Stock chart
Analyses on BIO View (4)
- March 26, 2026March 26, 2026
- Follow-up
BioView: Can Sanmed Rebuild Asia After the 2025 Collapse
The Sanmed renewal preserves BioView's option to rebuild its Asia channel, but after the 2025 collapse it is still a renewed contract without proof of repeat orders.
- Follow-up
BioView: How Much Flexibility Is Really Left After Adjustment Shares, Leases, and Bank Credit
BioView still has financial room, but it is much narrower than a positive-working-capital headline suggests: year-end cash was NIS 4.92 million, March 2026 added NIS 1 million of monthly renewable bank credit, and against that the company already carries a NIS 1.036 million adju…
- Follow-up
BioView: What Is Left of the Liquid-Biopsy Path After Inspira
The failed Inspira route shows that BioView was trying to externalize an IP and development package built around Angle, not a mature commercial engine. After expiry, the technology option remains inside the company, but so does the same funding bottleneck.
BioView 2025: Abbott Holds, Asia Shrinks, and Funding Is Still the Bottleneck
BioView is currently leaning on an existing service and sales base, mainly through Abbott and North America, but it still does not have enough funding room to comfortably carry both its development agenda and its liquid-biopsy optionality.
